Baird raised the firm’s price target on Iovance Biotherapeutics (IOVA) to $4 from $3 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results which showed nice momentum ending 2025 and continuing margin improvements into 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IOVA:
- Iovance Biotherapeutics price target raised to $11 from $10 at Barclays
- Iovance upgraded to Outperform from Market Perform at Citizens
- Iovance Biotherapeutics price target lowered to $16 from $17 at Chardan
- Iovance Biotherapeutics: Strengthening Commercial Momentum and Expanding Amtagvi Runway Support Buy Rating
- Midday Fly By: Home Depot reports Q4 beat, AMD and Meta expand partnership